PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma,OncoImmunology

当前位置： X-MOL 学术 › Oncoimmunology › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma
OncoImmunology ( IF 7.2 ) Pub Date : 2023-10-19 , DOI: 10.1080/2162402x.2023.2267744
Niklas Klümper _{1,

2,

3} , Lennert Wüst _{3,

4} , Jonas Saal _{3,

5} , Damian J Ralser _{2,

3,

6} , Romina Zarbl _{3,

4} , Jonas Jarczyk ₇ , Johannes Breyer _{8,

9} , Danijel Sikic _{9,

10,

11} , Bernd Wullich _{9,

10,

11} , Christian Bolenz ₁₂ , Florian Roghmann ₁₃ , Michael Hölzel _{2,

3} , Manuel Ritter _{1,

3} , Sebastian Strieth _{3,

4} , Arndt Hartmann _{9,

10,

14,

15} , Philipp Erben ₇ , Ralph M Wirtz ₁₆ , Jennifer Landsberg _{3,

17} , Dimo Dietrich _{3,

4} , Markus Eckstein _{9,

10,

14,

15}

Affiliation

Department of Urology and Pediatric Urology, University Medical Center Bonn (UKB), Bonn, Germany.
Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, Germany.
Center for Integrated Oncology, Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Germany.
Department of Otorhinolaryngology, University Medical Center Bonn (UKB), Bonn, Germany.
Medical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Medical Center Bonn (UKB), Bonn, Germany.
Department of Gynaecology and Gynaecological Oncology, University Medical Center Bonn (UKB), Bonn, Germany.
Department of Urology and Urosurgery, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Department of Urology, Caritas Hospital St. Josef, University of Regensburg, Regensburg, Germany.
Center for Integrated Oncology, Bavarian Center for Cancer Research (Bayerisches Zentrum für Krebsforschung, BZKF), Erlangen, Germany.
Center for Integrated Oncology, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
Department of Urology, University Hospital Ulm, Ulm, Germany.
Department of Urology, Ruhr-University Bochum, Herne, Germany.
Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Center for Integrated Oncology, STRATIFYER Molecular Pathology GmbH, Cologne, Germany.
Department of Dermatology and Allergy, University Medical Center Bonn (UKB), Bonn, Germany.

PD-L1 status assessed by immunohistochemistry (IHC) has failed to reliably predict outcomes for patients with metastatic urothelial carcinoma (mUC) on immune checkpoint blockade (ICB). PD-L1 promot...

中文翻译：